Drug Profile
MER 3001
Alternative Names: MER3001Latest Information Update: 18 Oct 2021
Price :
$50
*
At a glance
- Originator Mercia Pharma Inc
- Class Antihyperglycaemics
- Mechanism of Action Regulatory T-lymphocyte stimulants; Th2 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 17 Jan 2018 MER 3001 is still in phase II trials for Type 1 diabetes mellitus in USA (Mercia Pharma pipeline, January 2018)
- 08 Dec 2015 Phase-II clinical trials in Type-1 diabetes mellitus in USA (unspecified route)